Lanreotide Acetate Injection Shortage
Last Updated: March 3, 2025
Status: Current
Products Affected - Description
-
- Lanreotide acetate subcutaneous injection, Cipla USA, 120 mg/0.5 mL, prefilled syringe, NDC 69097-0870-67
- Lanreotide acetate subcutaneous injection, Exelan Pharmaceuticals, 120 mg/0.5 mL, prefilled syringe, NDC 76282-0720-67
Reason for the Shortage
-
- Cipla did not provide a reason for the shortage.
- Exelan did not provide a reason for the shortage.
- Ipsen Biopharmaceuticals has Somatuline Depot available.
Available Products
-
- Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 120 mg/0.5 mL, prefilled syringe, NDC 15054-1120-04
- Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 60 mg/0.2 mL, prefilled syringe, NDC 15054-1060-04
- Somatuline Depot subcutaneous injection, Ipsen Biopharmaceuticals, 90 mg/0.3 mL, prefilled syringe, NDC 15054-1090-04
Estimated Resupply Dates
-
- Cipla has lanreotide 120 mg/0.5 mL prefilled syringes on intermittent back order and the company is releasing supplies as they become available.
- Exelan has lanreotide 120 mg/0.5 mL prefilled syringes on back order and the company estimates a release date in the first half of 2025.
Updated
Updated March 3, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 9, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.